Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 28 Jul 2026

Continuing ADT During Lu-177 PSMA Therapy: What the Evidence Shows

Lutetium Lu-177 vipivotide tetraxetan is always given alongside maintained androgen deprivation therapy. Here is what the VISION trial evidence shows about combining both treatments, why the biology supports it, and what to expect.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 28 Jul 2026
Continuing ADT During Lu-177 PSMA Therapy: What the Evidence Shows

Short answer: Yes. If you are receiving lutetium Lu-177 vipivotide tetraxetan (brand name Pluvicto) for metastatic castration-resistant prostate cancer (mCRPC), your care team will almost certainly keep androgen deprivation therapy (ADT) running throughout treatment. Every major clinical trial for this radioligand therapy required patients to maintain castrate testosterone levels. Stopping ADT during treatment is not standard practice, and the evidence gives clear reasons for that.

This article is for men with mCRPC, which is prostate cancer that has kept growing despite hormone treatment. If you are asking what role ADT plays during Lu-177 PSMA therapy, why the clinical data supports continuing it, and what to watch for when both treatments run together, this article addresses these questions.

What Is ADT and Why Does It Still Matter When the Cancer Is Castration-Resistant?

Androgen deprivation therapy (ADT) lowers the amount of testosterone in your body. Testosterone acts like fuel for most prostate cancer cells. ADT stops that fuel by either removing the testicles surgically (orchiectomy) or by using ongoing injectable medications - called GnRH agonists or antagonists - that stop the body from producing testosterone.

The term castration-resistant is often misunderstood. It does not mean the cancer is completely independent of testosterone. It means the cancer has found ways to keep growing even at very low testosterone levels. Research shows that keeping testosterone in the castrate range still slows disease progression in most men with mCRPC. If ADT is stopped, testosterone can rise again quickly, and that may accelerate tumor growth. For this reason, oncologists keep castration as a backbone of mCRPC care, regardless of what additional therapies are layered on top.

What Did the VISION Trial Actually Require About ADT?

The VISION trial was the pivotal phase 3 study that supported the FDA's 2022 approval of lutetium Lu-177 vipivotide tetraxetan for mCRPC. It enrolled men who had already received at least one androgen receptor pathway inhibitor (ARPI) - such as enzalutamide or abiraterone - and one or two courses of taxane-based chemotherapy.

A key enrollment requirement was that all patients had to have either undergone surgical castration or be actively maintaining castrate serum testosterone through ongoing medical ADT. Castrate testosterone - defined in most oncology protocols as below 50 nanograms per deciliter (ng/dL) - was a protocol requirement, not an optional add-on. In the trial, patients received the radioligand every 6 weeks for up to 6 cycles. ADT continued throughout that entire period.

In 2025, the FDA expanded the approval based on the PSMAfore trial, which enrolled pre-chemotherapy mCRPC patients who had progressed on one ARPI. Those patients were also required to be in a state of medical or surgical castration at study entry.

Both approval pathways were built entirely on trial populations where castrate testosterone was actively maintained throughout treatment. There is no approved clinical dataset showing outcomes when ADT is stopped during radioligand therapy, because that was not how either trial was designed.

Does ADT Help Lu-177 PSMA Therapy Work Better?

Maintaining ADT during Lu-177 PSMA therapy also makes biological sense. ADT - and androgen receptor blockers in particular - appears to increase the expression of PSMA on prostate cancer cell surfaces.

PSMA (prostate-specific membrane antigen) is the protein that lutetium Lu-177 vipivotide tetraxetan targets. The radioligand finds PSMA on cancer cell surfaces and delivers targeted radiation directly to those cells. To understand this mechanism in more depth, the article on how Lu-177 PSMA works and what theranostics means explains it in plain language. If ADT increases PSMA on cancer cells, more radioligand can bind to and treat those cells.

Lab and animal studies support this pattern. Preclinical research published in Nuclear Medicine and Biology found that androgen receptor inhibition increased PSMA expression in both androgen-sensitive and castration-resistant prostate cancer cell lines. Lab studies also show that ADT pre-treatment increased DNA damage from radioligand therapy in mouse models. A review of published radioligand therapy combination evidence also notes that PSMA expression rises with androgen deprivation - a biological property that may strengthen PSMA targeting in the context of ongoing castration.

These findings have real limits, though. Most PSMA upregulation data comes from preclinical models, not from large clinical trials designed to test this mechanism directly in patients. Some preclinical studies found that despite increased DNA damage, combining treatments did not reduce tumors more than radioligand therapy alone. Researchers are still studying what these findings mean for patients.

What the evidence does say clearly is this: castration was maintained in every pivotal Lu-177 PSMA trial. There is no approved framework for stopping it during treatment, and doing so carries unknown risk.

What Side Effects Should You Expect When ADT and Lu-177 PSMA Run Together?

Both treatments have their own side effect profiles. Running them together means you may experience effects from both. Understanding which treatment causes which symptom helps you report them and get the right support.

Lutetium Lu-177 vipivotide tetraxetan commonly causes:

  • Dry mouth and taste changes, from mild effects on the salivary glands
  • Fatigue
  • Nausea, usually mild and manageable with anti-nausea medication
  • Drops in red blood cells, white blood cells, or platelets - monitored with blood tests between cycles
  • Mild changes in kidney function in some patients, also tracked regularly

Long-term ADT adds its own set of effects:

  • Hot flashes and night sweats
  • Fatigue and reduced muscle mass
  • Loss of bone density over time, which worsens with longer ADT use
  • Sexual dysfunction, including reduced libido and erectile changes
  • Mood changes in some men

Fatigue appears in both lists. When you take both treatments, you may feel more tired than from either one alone. Treatment may still be working even if you feel fatigued. Keeping a simple daily energy log can help you and your care team spot patterns. Tell your team if fatigue interferes with your daily life, because adjusting your schedule, nutrition, and sleep can help.

Bone health deserves specific attention. ADT accelerates bone loss over time, and many men with mCRPC already have bone metastases that put additional strain on the skeleton. Your care team will likely monitor bone density and may prescribe bone-protective medications alongside the radioligand therapy. Talk to your oncologist before taking any supplement, because some can interact with cancer treatments.

Sexual side effects are worth naming directly. ADT reduces testosterone to very low levels, which typically leads to reduced libido and changes in erectile function. Adding radioligand therapy does not reverse this effect. The article on erectile dysfunction during Lu-177 PSMA therapy covers what patients commonly experience and what management options exist during the combined treatment period.

What If You Have Already Been Through Multiple Lines of Hormone Therapy?

Many men who ask about Lu-177 PSMA therapy have already been through two ARPIs, chemotherapy, or both. At that point, it is reasonable to wonder if ADT still helps. The answer is yes - stopping it can let testosterone rise again and speed up disease.

The clinical evidence and current oncology practice say: yes, keep maintaining castrate testosterone. The cancer may be highly resistant, but stopping ADT can still cause a testosterone rebound that risks accelerating disease. The VISION trial enrolled heavily pre-treated patients who had already progressed on ARPI and taxane therapy, and all remained on ADT throughout the radioligand treatment.

If you are unsure whether your prior treatment history affects your eligibility for Lu-177 PSMA, the article on Lu-177 PSMA eligibility after multiple hormone therapy failures covers this in detail. Having had prior ARPI therapy is actually a requirement under the VISION trial pathway, not a disqualifier. What matters most for eligibility is your PSMA-PET scan result, kidney function, and current blood counts.

If you want an expert second opinion before making any treatment decisions, you can request a Lu-177 eligibility review through Art of Healing Cancer, where the nuclear medicine team can assess your scan results and prior treatment history and tell you whether radioligand therapy fits your case and what alternatives exist if it doesn't.

Practical Questions to Raise With Your Care Team

When you discuss ADT continuation alongside Lu-177 PSMA therapy, these are the questions worth preparing:

  • Is my current testosterone level in the castrate range? Most oncology protocols define castrate testosterone as below 50 ng/dL; some newer guidelines use below 20 ng/dL as the target. Your team can tell you where you stand.
  • Which form of ADT am I on - medical or surgical? Both are acceptable for eligibility under the trial-supported approval pathways.
  • Am I also taking an ARPI alongside ADT? The PSMAfore pathway covers men who progressed on one ARPI while on ADT. Your team will review what this means for sequencing decisions.
  • What is my bone density, and do I need a bone-protective medication? ADT accelerates bone loss, and this question matters more with prolonged use.
  • Are there side effects I am already managing on ADT that may be amplified by radioligand therapy? Your team needs a full picture of your current symptom burden before starting a new treatment.

If you would like a review of your eligibility or want a second opinion on your treatment options, you can send your case details to the Lutetium Therapy team. If Lu-177 PSMA is not the right fit, a second opinion on alternative options is also available.

When to Talk to Your Doctor

Speak to your oncologist or nuclear medicine team if:

  • You are considering stopping or changing your ADT regimen around the time of radioligand therapy
  • You are experiencing worsening fatigue, bone pain, or other new symptoms during combined treatment
  • You want to understand what your current testosterone level means for your eligibility and treatment plan
  • You have questions about bone protection or supplement options during this period
  • You are weighing a second opinion on your overall mCRPC treatment strategy

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Do I have to stop ADT before starting Lu-177 PSMA therapy?

No. You do not stop ADT before or during lutetium Lu-177 vipivotide tetraxetan treatment. The opposite is true: every major clinical trial, including the pivotal VISION and PSMAfore trials that led to FDA approval, required patients to be in a state of medical or surgical castration at the start of and throughout the treatment period. Your oncologist will confirm that your testosterone level is in the castrate range before each cycle begins.

Why do doctors keep ADT going even after the cancer is castration-resistant?

Castration-resistant does not mean the cancer no longer responds to low testosterone - it means the cancer has adapted to grow despite it. Stopping ADT can still cause a testosterone rebound that risks accelerating disease progression. Maintaining castrate testosterone remains part of the standard-of-care backbone for mCRPC, regardless of what additional therapies are added. All major clinical trials in this setting require its continuation throughout the treatment course.

Can ADT make Lu-177 PSMA therapy work better?

Possibly. Laboratory and animal research suggests that androgen deprivation - especially with androgen receptor blockers - increases the expression of PSMA on prostate cancer cell surfaces. Because lutetium Lu-177 vipivotide tetraxetan targets PSMA directly, higher PSMA expression could in theory allow more radioligand molecules to bind to cancer cells. However, this has not yet been confirmed in large randomized clinical trials that specifically tested ADT-on versus ADT-off groups during radioligand therapy. The preclinical evidence is promising but not conclusive.

Will combining ADT and Lu-177 PSMA cause worse side effects?

Both treatments independently cause fatigue, so tiredness may be more noticeable when they run together. ADT also causes bone loss, hot flashes, and sexual changes over time. Lutetium Lu-177 vipivotide tetraxetan can cause dry mouth, mild nausea, and drops in blood counts. Your care team will monitor your blood counts and kidney function between cycles. Most side effects are manageable with the right support - tell your oncologist about any that are affecting your daily life.

What testosterone level is required before starting Lu-177 PSMA treatment?

Clinical trial protocols for lutetium Lu-177 vipivotide tetraxetan require patients to have castrate testosterone, which most oncology guidelines define as below 50 nanograms per deciliter (ng/dL). Some newer guidelines and trial protocols use a more stringent threshold of below 20 ng/dL. Your oncologist will check your testosterone level as part of the pre-treatment screening process. If your level is above the castrate threshold, your ADT regimen may need to be reviewed before radioligand therapy begins.

If multiple hormone therapies have failed, can I still be eligible for Lu-177 PSMA?

Potentially yes - it depends primarily on your PSMA-PET scan result and other factors such as kidney function and blood counts. Under the original VISION trial pathway, having received at least one ARPI and one or two taxane courses is actually a requirement, not a disqualifier. Under the PSMAfore pathway, progression on at least one ARPI in a pre-chemotherapy setting is the qualifying criterion. A specialist eligibility review can clarify whether your specific treatment history and scan results fit the approved criteria.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Lu-177 PSMA and ADT: Should You Continue Both? | lutetium-therapy